CLINICAL FEATURES AND INCIDENCE RATE OF OCULAR COMPLICATIONS IN PUNCTATE INNER CHOROIDOPATHY
CLINICAL FEATURES AND INCIDENCE RATE OF OCULAR COMPLICATIONS IN PUNCTATE INNER CHOROIDOPATHY
复制标题
DOI：
10.1097/iae.0000000000000125
复制
发表时间：
2014-08-01
影响因子：
3.3
通讯作者：
Thorne, Jennifer E.
中科院分区：
文献类型：
--
作者：
Leung, Theresa G.;Moradi, Ahmadreza;Thorne, Jennifer E.
目的：目的探讨点状内脉络膜病变的临床特点及眼部并发症的发生率。方法：本研究采用回顾性队列研究方法，在单中心学术实践环境中进行。确定了1984年至2012年在约翰霍普金斯大学威尔默眼科研究所诊断为点状内脉络膜病变的患者。收集人口统计学和临床特征，包括脉络膜新生血管（CNV）和结构并发症的存在。结果：31例（59眼）患者纳入本研究。24例患者（47只眼）的随访数据可用，平均随访时间为3.4年（范围：2个月至8.7年）。在随访的患眼中，视力损害至20/50或更差的发生率为0.06/眼年（EY）（95%置信区间，0.022/EY-0.114/EY）。视力丧失至20/200或更差的发生率为0.006/EY（95%置信区间，0.0001/EY-0.034/EY）。36只眼（77%）的最终视力为20/40或更好。所有13例随访时间>= 3年的患者在就诊后3年时至少有1只眼睛的视力>= 20/40。三分之二（67%）接受免疫调节药物治疗的随访患者没有新发或复发的CNV。然而，这不是统计学显著差异。随访的3只眼CNV复发，发生率为0.04/EY（95%置信区间，0.008/EY-0.12/EY）。随访中有2眼发生新的CNV，发生率为0.02/EY（95%可信区间为0.002/EY ~ 0.066/EY）。新发CNV和复发CNV的发生率分别为0.02/EY和0.04/EY。
Purpose: To study the clinical features and incidence rate of ocular complications in patients with punctate inner choroidopathy.Methods: This is a retrospective cohort study conducted in a single-center academic practice setting. Patients diagnosed with punctate inner choroidopathy at the Wilmer Eye Institute, Johns Hopkins University from 1984 to 2012 were identified. Demographics and clinical features including the presence of choroidal neovascularization (CNV) and structural complications were collected. Main outcome measures, including visual impairment and incidence rate of ocular complications, were analyzed.Results: Thirty-one patients (59 eyes) were included in the study. Follow-up data were available for 24 patients (47 eyes) with a mean follow-up time of 3.4 years (range, 2 months to 8.7 years). In the affected eyes with follow-up, the incidence rate of visual impairment to 20/50 or worse was 0.06 per eye-year (EY) (95% confidence interval, 0.022/EY-0.114/EY). The incidence rate of visual loss to 20/200 or worse was 0.006/EY (95% confidence interval, 0.0001/EY-0.034/EY). Thirty-six eyes (77%) had an ultimate visual acuity of 20/40 or better. All of the 13 patients with more than >= 3 years of follow-up had a visual acuity of >= 20/40 in at least 1 eye at 3 years after presentation. Two thirds of the follow-up patients (67%) on immunomodulatory drug therapy did not have new or recurrent CNV. However, this was not a statistically significant difference. Three eyes with follow-up had recurrence of CNV for an incidence rate of 0.04/EY (95% confidence interval, 0.008/EY-0.12/EY). Two eyes developed new CNV during follow-up for an incidence rate of 0.02/EY (95% confidence interval, 0.002/EY-0.066/EY).Conclusion: The visual prognosis in most cases of punctate inner choroidopathy is very good. The incidence rate of new CNV and recurrent CNV was 0.02/EY and 0.04/EY, respectively.